Pharmacological treatment of obesity in clinical practice
Omercan Topaloglu, Ibrahim Sahin
DOI: 10.5455/medscience.2021.05.151 · Page: 651-7 · 125 Views · 9 Downloads · 0 Citations
Abstract
Abstract
Anti-obesity medications may be considered in the subjects with BMI ≥30 kg/m2, or with BMI 27-29.9 kg/m2 and weight-related comorbidities, whom weight reduction is not achieved via lifestyle modifications alone. If weight loss is inadequate (
Keywords : Obesity; pharmacological treatment; obesity treatment; liraglutide; orlistat